collaboration
Mark Foundation, Johns Hopkins University Invest $10M in Cancer Immunotherapy Research
The funds will go toward new technologies, including genomics and imaging platforms, to identify why certain patients do and do not respond to cancer immunotherapy.
Affini-T, Metagenomi Ink Deal to Develop Gene-Edited Cell Therapies for Solid Cancers
The firms will marry their respective technologies to develop gene-edited T-cell receptor therapies against solid tumor targets such as KRAS and p53.
Syapse, Pierian Partner to Advance Precision Oncology at Central Florida Health System
The firms' real-world data analytics and genomic interpretation knowledgebase may help AdventHealth clinicians identify treatment opportunities for patients.Â
Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Datopotamab Deruxtecan for TNBC
The firms are evaluating the anti-TROP2 antibody-drug conjugate versus chemo for previously untreated TNBC patients who aren't eligible for checkpoint inhibitors.
Telix Pharmaceuticals, RefleXion Medical to Develop Illuccix-Guided Radiotherapy for Prostate Cancer
The firms plan to begin a clinical trial of the imaging agent and radiotherapy in 2023 and seek regulatory approval in the US.